Rigel Pharmaceuticals | RIGL - Ordinary Share Capital


Rigel Pharmaceuticals reported $17K in Ordinary Share Capital for its fiscal quarter ending in June of 2024.





Ordinary Share Capital Change Date
Agenus USD 35.32M 2.51M Dec/2025
Amgen USD 540M 1000K Mar/2026
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 137.39M 1.69M Dec/2025
AstraZeneca USD 1.55B 73K Mar/2026
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Celldex Therapeutics USD 66.57M 20K Mar/2026
Daiichi Sankyo JPY 1.85B 9K Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Halozyme Therapeutics USD 118.52M 741K Mar/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Intrexon USD 0 0 Jun/2024
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
Karyopharm Therapeutics USD 18.31M 18.3M Dec/2025
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
MacroGenics USD 63.32M 60K Dec/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Pfizer USD 5.7B 13M Mar/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Veracyte USD 79.79M 743K Mar/2026